Press Releases
Media Library
Social Media
Analyst Coverage
Annual and Interim Reports
Annual General Meeting
Annual Report 2016
Conflict Minerals Disclosure
Debt Investors
Dividend
Email Alerts
Events
Financial Highlights
Investor News
Our Strategy
Quarterly Results and Presentations
Recent Acquisitions
Shareholder Information
Stock Information
WHO WE ARE
Our Story
Rare Champions
Responsibility
Leadership
How We Operate
PATIENTS
Patient Services
Patient Advocacy
Therapeutic Areas
Humanitarian Access
Scholarships
R&D
Our R&D Strategy
EDUCATIONAL GRANTS
Science & Innovation
Investigator Initiated Research (IIR)
Pipeline
Clinical Trials
Collaborations
PRODUCTS
Product List
Manufacturing
Postmarketing Commitments
CAREERS
Search & Apply
Diversity & Inclusion
Culture & Values
Growing Your Career
Benefits
US Internship Program
Work Life Balance
Employee Profiles
Shire Delivers 7% Product Sales Growth and Robust Pipeline Progress in Q1 2018
Rule 2.9 Announcement
Shire announces revised proposal and extension of PUSU deadline to 8 May 2018
Result of the 2018 Annual General Meeting
Statement re revised proposal
Holding(s) in Company
Statement re Proposal from Takeda Pharmaceutical Company Limited
The Swiss Agency for Therapeutic Products (Swissmedic) Validates Shire’s Marketing Authorization Application (MAA) for Investigational Hereditary Angioedema (HAE) Treatment Lanadelumab
Shire to announce first quarter 2018 results
FDA approves VONVENDI® [von Willebrand factor (recombinant)] for perioperative management of bleeding in adult patients with von Willebrand disease[1]
Shire Announces Sale of Oncology Business to Servier for $2.4 Billion
Shire plc: Form 8 Opening Position Disclosure – Takeda Pharmaceutical Company Limited
Shire plc: Form 8 Opening Position Disclosure – Shire plc
LOAD MORE
Learn more
We make decisions that put patients first.
By following this link you will be leaving a Shire controlled website for a third party website. Please note that Shire is not responsible or liable for any third party website and the website may not be appropriate for all audiences.